Congratulations to the Centre’s 2022 Honours students on their scholarship awards and we wish them all the best for their research and training
Validation of the Male Depression Risk Scale short form in a cross-sectional study of Australian men. Herreen D, Rice S, Zajac I. Brief assessment of male depression in clinical care:BMJ Open. 2022 Mar 28;12(3):e053650. doi: 10.1136/bmjopen-2021-053650.
Contact: Dr Ian Zajac
To celebrate International Women’s Day, the Centre is highlighting some of the fantastic women of men’s health that have been supported by the Centre and are achieving great work in the field. FCMHW encourages and commends the involvement of women in men’s health and hopes to further support it in the future.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. Mak B, Lin HM, Kwan EM, Fettke H, Tran B, Davis ID, Mahon K, Stockler MR, Briscoe K, Marx G, Zhang A, Crumbaker M, Tan W, Huynh K, Meikle TG, Mellett NA, Hoy AJ, Du P, Yu J, Jia S, Joshua AM, Waugh DJ, Butler LM, Kohli M, Meikle PJ, Azad AA, Horvath LG. BMC Med. 2022 Mar 25;20(1):112. doi: 10.1186/s12916-022-02298-0.
Contact: Lisa Butler
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
Lin HM, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, Kwan EM, Fettke H, Tran B, Davis ID, Mahon KL, Zhang A, Stockler MR, Briscoe K, Marx G, Crumbaker M, Stricker PD, Du P, Yu J, Jia S, Scheinberg T, Fitzpatrick M, Bonnitcha P, Sullivan DR, Joshua AM, Azad AA, Butler LM, Meikle PJ, Horvath LG.
EBioMedicine. 2021 Oct 14;72:103625. doi: 10.1016/j.ebiom.2021.103625. PMID: 34656931.
Contact: Lisa Butler
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, Mahon KL, Mak B, Sutherland PD, Shepherd A, Mellett N, Docanto M, Giles C, Centenera MM, Butler LM, Meikle PJ, Horvath LG.
Prostate Cancer Prostatic Dis. 2021 Mar 21. doi: 10.1038/s41391-021-00338-z.
Contact: Lisa Butler
Immunotherapy approaches for prostate cancer have been largely unsuccessful, despite many clinical trials. We propose that harnessing the immune system to treat prostate cancer first requires a better understanding of the unique biology of this disease. The objective of this research program is to investigate the interplay between androgen receptor signalling and immunity in prostate cancer
Contact: A/Prof Luke Selth
